Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940308 | 0.90 | FFAR1 (0.47) | CD274TDO2FFAR1FFAR4 | |
| SCHEMBL16845958 | 0.90 | FFAR1 (0.47) | CD274TDO2FFAR1FFAR4 | |
| SCHEMBL18959423 | 0.90 | CD274 (0.38) | CD274TDO2FFAR1FFAR4SCN3A | |
| SCHEMBL23952786 | 0.89 | TDO2 (0.38) | CD274TDO2FFAR1FFAR4SCN3A | |
| SCHEMBL18959427 | 0.87 | FFAR1 (0.43) | CD274FFAR1FFAR4 | |
| SCHEMBL18959428 | 0.87 | FFAR1 (0.46) | CD274FFAR1FFAR4 | |
| SCHEMBL18959416 | 0.85 | CD274 (0.48) | CD274FFAR1 | |
| SCHEMBL18959406 | 0.81 | FFAR1 (0.38) | CD274FFAR1FFAR4 | |
| SCHEMBL15471341 | 0.80 | FFAR1 (0.48) | FFAR1FFAR4ALOX5APFEN1 | |
| SCHEMBL18940303 | 0.80 | FFAR1 (0.44) | CD274TDO2FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | CD274 4582/4885TDO2 3275/4885FFAR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.